Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
semaglutide | increase | first-phase insulin secretion | participants with type 2 diabetes | 2.5-fold | significantly increased | #1 |
semaglutide | increase | second-phase insulin secretion | participants with type 2 diabetes | 2.5-fold | significantly increased | #2 |
semaglutide | increase | insulin AUC | participants with type 2 diabetes | 2.5-fold | significantly increased | #3 |
semaglutide | increase | C-peptide AUC | participants with type 2 diabetes | 2.5-fold | significantly increased | #4 |
semaglutide | decrease | glucose AUC | participants with type 2 diabetes | 50% | significantly reduced | #5 |
semaglutide | decrease | fasting plasma glucose | participants with type 2 diabetes | 2.5 mmol/L | significantly reduced | #6 |
semaglutide | decrease | HbA1c | participants with type 2 diabetes | 1.2% | significantly reduced | #7 |
semaglutide | increase | beta cell function | participants with type 2 diabetes | - | significantly improved | #8 |
semaglutide | increase | glycaemic control | participants with type 2 diabetes | - | significantly improved | #9 |
AIMS/HYPOTHESIS: Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed. METHODS: In this single-centre, double-blind, placebo-controlled, parallel-group trial, conducted at the Profil Institut für Stoffwechselforschung, Germany, 75 adult (aged 18-64 years) participants with type 2 diabetes (eligibility: HbA RESULTS: In total, 37 participants received semaglutide and 38 received placebo. Following IVGTT, for insulin, both AUC CONCLUSIONS/INTERPRETATION: Twelve weeks of once-weekly treatment with semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT02212067 FUNDING: The study was funded by Novo Nordisk A/S.